Intellia Therapeutics, Alnylam seen as potential Regeneron targets, analyst says
Stocks making the biggest moves in the premarket: Boeing, Intellia Therapeutics, Perion Network & more - CNBC
1.11BUSD
See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US45826J1051
CUSIP
45826J105
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-0.10
Book Value
7.53
Dividend Share
-
Dividend Yield
-
Earnings Share
-5.23
Wall Street Target Price
37.30
EPS Estimate Current Year
-4.16
EPS Estimate Next Year
-3.86
EPS Estimate Current Quarter
-1.2711
EPS Estimate Next Quarter
-1.1578
Most Recent Quarter
-
Revenue TTM
45,569,000
Gross Profit TTM
-417,321,984
EBITDA
-530,796,000
Profit Margin
0.00%
Return On Assets TTM
-30.12%
Return On Equity TTM
-57.92%
Revenue Per Share TTM
0.452
Qtly Revenue Growth YOY
-42.50%
Diluted Eps TTM
-5.23
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
23.2993
Price Book MRQ
1.3613
Enterprise Value Revenue
14
Enterprise Value EBITDA
-5
99.35
3.29%203.85
2.01%80.40
0.55%152.82
0.06%538.11
0.04%547.60
0.00%240.50
-2.03%545.20
-0.21%324.00
-0.05%459.50
-0.00%